HLTH 8430 Week 11 Board Financial Recommendation Example

Board Recommendation: Phased Laboratory Consolidation Funded From Reserves, With a Stop Condition

Student Name

Walden University

HLTH 8430: Healthcare Financial Management

Instructor Name

Month Day, Year

Board Recommendation: Phased Laboratory Consolidation Funded From Reserves, With a Stop Condition

Motion

Resolved, that the Board of Directors of Harmon Valley Health approves the revised consolidation of the system's two hospital laboratories at a total cost not to exceed $17.0 million, illustrative; that the project be funded from board-designated reserves; that Phase 1, establishing the core laboratory at the flagship hospital and bringing reference work in-house, at a cost not to exceed $10.0 million, proceed now; and that Phase 2, moving the smaller hospital's routine testing to the core laboratory, at a cost not to exceed $7.0 million, be released only if the smaller hospital's rapid-response laboratory turns around at least nine in ten urgent tests within an hour of receipt in each of two consecutive quarters after Phase 1 is complete, as certified by the Finance Committee.

Background

Harmon Valley Health, the composite nonprofit system studied all term, operates two hospitals, and each runs a full laboratory. In Week 7, management proposed consolidating routine testing into one automated core laboratory to reduce reagent and staffing costs and to bring specialized tests in-house. The Finance Committee asked for the proposal to be tested against the strongest objections before reaching the board. This recommendation reflects that testing.

Summary of the Analysis

Discounted at the system's 7% cost of capital over ten years, the original proposal came out $7.9 million ahead on base volume, but only $0.9 million ahead on conservative volume. When four objections were priced at their strongest, turnaround, transport, concentration and outreach revenue, the original proposal turned negative. The counterargument brief then priced a revised design, adding an expanded rapid-response menu, a courier and specimen stability protocol, backup with a reference laboratory and a retained patient service center for nearby physician offices. Discounted at the same rate, that design comes out $1.6 million ahead in the base case and $5.4 million behind under conservative volume. Phasing limits the system's exposure: Phase 1 captures most of the reagent and reference-work savings at the flagship, while Phase 2, which carries most of the outreach and turnaround risk, is committed only after evidence.

Funding: Reserves or Borrowing

Drawing $17 million from designated reserves takes days cash on hand from 212 to roughly 206, still more than double the bond covenant's 100 days and above the peer median. A 20-year loan for the same sum, priced near 5.5%, carries roughly $1.4 million of annual debt service and would trim coverage by a few hundredths, to just under 1.9 times. Coverage, not liquidity, is the system's binding constraint, as the Week 5 ratio brief showed; it sits closest to its covenant minimum of 1.25 and limits future borrowing for larger needs, including the deferred facility replacement identified in Week 3. Using reserves preserves debt capacity for those needs. Because the board itself set these funds aside, it can also release them; the reporting standard classes them as net assets without donor restrictions (Financial Accounting Standards Board, 2016). The cost of this choice is lower investment income on the reserves used, which is smaller than the interest cost of borrowing.

Alternatives Rejected

Doing nothing keeps two full laboratories, avoids all four objection costs and forgoes the savings. It leaves both laboratories facing analyzer replacement within a few years at duplicate cost, so it is not free; it defers a capital decision rather than avoiding it.

The original Week 7 proposal is rejected because, with its objections priced, it loses value even on base-case volume.

Full consolidation in one phase is rejected because it commits all $17 million before the system knows whether turnaround can be protected and how much outreach revenue will be lost, the two uncertainties that decide whether the project earns its cost of capital.

Borrowing to fund the project is rejected because it uses debt capacity the system will need for facility replacement, for a project small enough to fund from reserves.

Risk the Board Accepts

The principal risk is that outreach revenue loss is larger than projected. The revised design assumes that retaining a patient service center and courier pickup will limit the loss to about $250,000 a year. If physician offices move more work to commercial laboratories, Phase 2 could reduce the project's value below zero. By approving the motion, the board accepts that, on conservative volume, the revised design falls short of the 7% return the system requires, and that the stop condition on Phase 2 limits, but does not remove, that risk. Healthcare finance texts note that boards approving projects with narrow or negative conservative cases should do so explicitly and with measures in place (Cleverley & Cleverley, 2018), which is what this motion does.

Monitoring

The Finance Committee will review three measures quarterly.

Table 1

Measures the Finance Committee Will Review

Conclusion

Approving the motion commits $10 million now and up to $7 million later, from reserves, to a project that saves money in the base case, protects the system's debt capacity and limits its exposure to the risks that could make it a poor investment. The board will know within about a year of Phase 1 whether the conditions for Phase 2 are met. Capital budgeting texts describe staged commitments of this kind as a way to keep the option to stop when the main uncertainty has not yet resolved (Gapenski & Reiter, 2016). If the conditions are not met, the system will have gained a core laboratory at the flagship and kept a full laboratory at the smaller hospital, which is a defensible outcome in its own right.

References

Cleverley, W. O., & Cleverley, J. O. (2018). Essentials of health care finance (8th ed.). Jones & Bartlett Learning.

Financial Accounting Standards Board. (2016). Accounting Standards Update No. 2016-14: Not-for-profit entities (Topic 958): Presentation of financial statements of not-for-profit entities. Financial Accounting Standards Board.

Gapenski, L. C., & Reiter, K. L. (2016). Healthcare finance: An introduction to accounting and financial management (6th ed.). Health Administration Press.